Daniel  Von Hoff
Daniel Von Hoff
Chief Scientific Officer US Oncology, Chief Scientific Officer TGen, Distinguished Professor Mayo
Verified email at
Cited by
Cited by
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
HA Burris, MJ Moore, J Andersen, MR Green, ML Rothenberg, ...
Journal of clinical oncology 15 (6), 2403-2413, 1997
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ...
New England journal of medicine 369 (18), 1691-1703, 2013
Risk factors for doxorubicin-lnduced congestive heart failure
DD Von Hoff, MW Layard, P Basa, HL DAVIS Jr, AL Von Hoff, ...
Annals of internal medicine 91 (5), 710-717, 1979
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
PP Provenzano, C Cuevas, AE Chang, VK Goel, DD Von Hoff, ...
Cancer cell 21 (3), 418-429, 2012
Hypersensitivity reactions from taxol.
RB Weiss, RC Donehower, PH Wiernik, T Ohnuma, RJ Gralla, DL Trump, ...
Journal of clinical oncology 8 (7), 1263-1268, 1990
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ...
New England Journal of Medicine 361 (12), 1164-1172, 2009
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
C Heise, A Sampson-Johannes, A Williams, F Mccormick, DD Von Hoff, ...
Nature medicine 3 (6), 639-645, 1997
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ...
New England Journal of Medicine 361 (12), 1173-1178, 2009
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ...
Journal of Clinical Oncology 29 (34), 4548, 2011
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ...
Science translational medicine 4 (128), 128ra39-128ra39, 2012
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.
KE Noonan, C Beck, TA Holzmayer, JE Chin, JS Wunder, IL Andrulis, ...
Proceedings of the National Academy of Sciences 87 (18), 7160-7164, 1990
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open …
A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ...
The Lancet 387 (10018), 545-557, 2016
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ...
Journal of clinical oncology 22 (8), 1430-1438, 2004
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
ML Rothenberg, MJ Moore, MC Cripps, JS Andersen, RK Portenoy, ...
Annals of Oncology 7 (4), 347-353, 1996
Toxic effects of cis-dichlorodiammineplatinum (II) in man.
DD Von Hoff, R Schilsky, CM Reichert, RL Reddick, M Rozencweig, ...
Cancer treatment reports 63 (9-10), 1527-1531, 1979
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
D Mahadevan, DD Von Hoff
Molecular cancer therapeutics 6 (4), 1186-1197, 2007
Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development
EK Rowinsky, JJ Windle, DD Von Hoff
Journal of Clinical Oncology 17 (11), 3631-3652, 1999
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants
ML Hensley, KL Hagerty, T Kewalramani, DM Green, NJ Meropol, ...
Journal of clinical oncology 27 (1), 127-145, 2009
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial
D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ...
JNCI: Journal of the National Cancer Institute 107 (2), 2015
The system can't perform the operation now. Try again later.
Articles 1–20